🇺🇸 FDA
Pipeline program

M9140

MS202329_0010

Phase 2 small_molecule active

Quick answer

M9140 for Non-Small Cell Lung Cancer is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
Non-Small Cell Lung Cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials